Mysa Saad/X
Dec 8, 2025, 08:35
Dr. Mysa Saad Had Her First Oral Presentation at ASH25
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on X:
“Congrats to Dr. Mysa Saad on her first oral presentation at ASH25!
Post-hoc AVERT analysis: In cancer patients on apixaban prophylaxis, concurrent antiplatelet/NSAID use ↑ clinically relevant bleeding (HR 1.78) with no VTE benefit.”
Follow the latest in Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria